bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
Authors: Bam Rakesh , Lown Patrick S. , Stern Lawrence A. , Sharma Karina , Wilson Katheryne E. , Bean Gregory R. , Lutz Amelie M. , Paulmurugan Ramasamy , Hackel Benjamin J. , Dahl Jeremy , Abou-Elkacem Lotfi
Published: April 2023

ABYB7-H3 positively stains B7-H3 expressed in the tissue sections from human breast cancer patients.
Figure S2 from Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
Authors: Bam Rakesh , Lown Patrick S. , Stern Lawrence A. , Sharma Karina , Wilson Katheryne E. , Bean Gregory R. , Lutz Amelie M. , Paulmurugan Ramasamy , Hackel Benjamin J. , Dahl Jeremy , Abou-Elkacem Lotfi
Published: April 2023

ABYB7-H3 binds to MS1hB7-H3 and RAW264.7 cells in a dose-dependent manner.
Table S4 from Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Authors: Weinmann Sheila , Leo Michael C. , Francisco Melanie , Jenkins Charisma L. , Barry Todd , Leesman Glen , Linke Steven P. , Whitworth Pat W. , Patel Rakesh , Pellicane James , Wärnberg Fredrik , Bremer Troy
Published: April 2023

Multivariable Cox proportional hazard regression analysis of alternative invasive score in relation to invasive breast event outcome, overall and by receipt of radiation therapy
Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Authors: Oza Amit M. , Matulonis Ursula A. , Alvarez Secord Angeles , Nemunaitis John , Roman Lynda D. , Blagden Sarah P. , Banerjee Susana , McGuire William P. , Ghamande Sharad , Birrer Michael J. , Fleming Gini F. , Markham Merry Jennifer , Hirte Hal W. , Provencher Diane M. , Basu Bristi , Kristeleit Rebecca , Armstrong Deborah K. , Schwartz Benjamin , Braly Patricia , Hall Geoff D. , Nephew Kenneth P. , Jueliger Simone , Oganesian Aram , Naim Sue , Hao Yong , Keer Harold , Azab Mohammad , Matei Daniela
Published: April 2023

Supplementary methods
Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Authors: Oza Amit M. , Matulonis Ursula A. , Alvarez Secord Angeles , Nemunaitis John , Roman Lynda D. , Blagden Sarah P. , Banerjee Susana , McGuire William P. , Ghamande Sharad , Birrer Michael J. , Fleming Gini F. , Markham Merry Jennifer , Hirte Hal W. , Provencher Diane M. , Basu Bristi , Kristeleit Rebecca , Armstrong Deborah K. , Schwartz Benjamin , Braly Patricia , Hall Geoff D. , Nephew Kenneth P. , Jueliger Simone , Oganesian Aram , Naim Sue , Hao Yong , Keer Harold , Azab Mohammad , Matei Daniela
Published: April 2023

Supplementary Figure S1 and supplementary tables
Figure S3 from Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes
Authors: Shin Myeong-Kyun , Payne Susan , Bilger Andrea , Matkowskyj Kristina A. , Carchman Evie , Meyer Dominique S. , Bentires-Alj Mohamed , Deming Dustin A. , Lambert Paul F.
Published: April 2023

Figure S3. Examination of the change of apoptosis status by treatment of TAK-228
Figure S5 from Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation
Authors: Savage Talicia , Pandey Sanjay , Guha Chandan
Published: April 2023

Splenic leukocyte populations in systemic PAM-RT treated mice.
Figure S4 from Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation
Authors: Savage Talicia , Pandey Sanjay , Guha Chandan
Published: April 2023

CD8/Treg ratio in treated lungs.
Supplementary figure legends from Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells
Authors: Mota Reyes Carmen , Teller Steffen , Muckenhuber Alexander , Konukiewitz Björn , Safak Okan , Weichert Wilko , Friess Helmut , Ceyhan Güralp O. , Demir Ihsan Ekin
Published: April 2023

Supplementary figure legends
Supplementary Data from The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Authors: Knepper Todd C. , Montesion Meagan , Russell Jeffery S. , Sokol Ethan S. , Frampton Garrett M. , Miller Vincent A. , Albacker Lee A. , McLeod Howard L. , Eroglu Zeynep , Khushalani Nikhil I. , Sondak Vernon K. , Messina Jane L. , Schell Michael J. , DeCaprio James A. , Tsai Kenneth Y. , Brohl Andrew S.
Published: April 2023

Figure S1
Figure S6AB from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary figure
Supplementary Data from The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Authors: Knepper Todd C. , Montesion Meagan , Russell Jeffery S. , Sokol Ethan S. , Frampton Garrett M. , Miller Vincent A. , Albacker Lee A. , McLeod Howard L. , Eroglu Zeynep , Khushalani Nikhil I. , Sondak Vernon K. , Messina Jane L. , Schell Michael J. , DeCaprio James A. , Tsai Kenneth Y. , Brohl Andrew S.
Published: April 2023

Figure S2
Figure S5 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Table S1 from PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models
Authors: Hernandez Ariel L. , Young Christian D. , Bian Li , Weigel Kelsey , Nolan Kyle , Frederick Barbara , Han Gangwen , He Guanting , Devon Trahan G. , Rudolph Michael C. , Jones Kenneth L. , Oweida Ayman J. , Karam Sana D. , Raben David , Wang Xiao-Jing
Published: April 2023

Supplementary Table S1 lists reagents used
Supplementary Data from Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma
Authors: Bhatia Shailender , Longino Natalie V. , Miller Natalie J. , Kulikauskas Rima , Iyer Jayasri G. , Ibrani Dafina , Blom Astrid , Byrd David R. , Parvathaneni Upendra , Twitty Christopher G. , Campbell Jean S. , Le Mai H. , Gargosky Sharron , Pierce Robert H. , Heller Richard , Daud Adil I. , Nghiem Paul
Published: April 2023

Figure S1, Table S1, Table S2
Supplementary Data from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Authors: Reardon David A. , Desjardins Annick , Vredenburgh James J. , O'Rourke Donald M. , Tran David D. , Fink Karen L. , Nabors Louis B. , Li Gordon , Bota Daniela A. , Lukas Rimas V. , Ashby Lynn S. , Duic J. Paul , Mrugala Maciej M. , Cruickshank Scott , Vitale Laura , He Yi , Green Jennifer A. , Yellin Michael J. , Turner Christopher D. , Keler Tibor , Davis Thomas A. , Sampson John H.
Published: April 2023

Web Extra Material - 2 tables and 3 figures
Supplementary Figure S2 from PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models
Authors: Hernandez Ariel L. , Young Christian D. , Bian Li , Weigel Kelsey , Nolan Kyle , Frederick Barbara , Han Gangwen , He Guanting , Devon Trahan G. , Rudolph Michael C. , Jones Kenneth L. , Oweida Ayman J. , Karam Sana D. , Raben David , Wang Xiao-Jing
Published: April 2023

Supplementary Figure S2 demonstrates the enrichment of Fanoni Anemia pathway genes as a function of SMAD4 levels (in TCGA analyses)
Figure A2 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Authors: Reardon David A. , Desjardins Annick , Vredenburgh James J. , O'Rourke Donald M. , Tran David D. , Fink Karen L. , Nabors Louis B. , Li Gordon , Bota Daniela A. , Lukas Rimas V. , Ashby Lynn S. , Duic J. Paul , Mrugala Maciej M. , Cruickshank Scott , Vitale Laura , He Yi , Green Jennifer A. , Yellin Michael J. , Turner Christopher D. , Keler Tibor , Davis Thomas A. , Sampson John H.
Published: April 2023

Figure A2 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Supplementary Table S1 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study
Authors: Buus Richard , Sestak Ivana , Barron Stephen , Loughman Tony , Fender Bozena , Ruiz Cesar Lopez , Dynoodt Peter , Wang Chan-Ju Angel , O'Leary Des , Gallagher William M. , Dowsett Mitch , Cuzick Jack
Published: April 2023

Patient characteristics. ER, estrogen receptor; IQR, interquartile range; BMI, Body Mass Index; mm, millimetre; HRT, Hormone Replacement Therapy.
Supplementary Table 2 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Primers used for semi-quantitative reverse transcriptase (RT)-PCR analysis.
Supplementary Figure S1 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study
Authors: Buus Richard , Sestak Ivana , Barron Stephen , Loughman Tony , Fender Bozena , Ruiz Cesar Lopez , Dynoodt Peter , Wang Chan-Ju Angel , O'Leary Des , Gallagher William M. , Dowsett Mitch , Cuzick Jack
Published: April 2023

Discovery and development of the OncoMasTR algorithm. ARACNe, Algorithm for the Reconstruction of Accurate Cellular Networks; ChIP, chromatin immunoprecipitation; MTR, master transcriptional regulator; RT-qPCR, reverse transcriptase quantitative polymerase chain reaction
Supplementary Figure 8 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Re-expression of RIPK3 induces necrosis of RIPK3-negative MM cells. M8, M12, M17 and MSTO211H cells were transduced with control WPI lentivirus or WPI lentivirus expressing RIPK3 cDNA for 24 hours before seeding in 96-well plates and assaying for cell viability (MTS assay) and release of LDH, an indicator of necrosis. Cells were assayed 48 hours post-seeding.
Figure S3 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Authors: Henderson Meredith C. , Silver Michael , Tran Quynh , Letsios Elias E. , Mulpuri Rao , Reese David E. , Lourenco Ana P. , LaBaer Joshua , Anderson Karen S. , Alpers Josie , Costantini Carrie , Rohatgi Nitin , Ali Haythem , Baker Karen , Northfelt Donald W. , Ghosh Karthik , Grobmyer Stephen R. , Polen Winnie , Wolf Judith K.
Published: April 2023

Figure S3: Breakdown of subjects excluded in the Provista-002 trial. Reasons for exclusion shown in legend.
Table S8 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S8
Supplementary Figure 1B from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Efficiency of infection of MM cell lines infected with a pWPI lentivirus that expresses GFP marker alone (pWPI, control) or with a pWPI lentivirus that expresses both GFP and either RIPK3 WT or RIPK3-KD. Representative images indicate efficiency of infection of RIPK3-negative MM cell lines M8 and M22. Photographs of GFP fluorescence and combined GFP plus brightfield were taken 24 h after the initiation of infection. Note that most cells infected with pWPI-RIPK3 WT were floating, dead cells.
Table S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S2
Figure S6 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Figure S6
Figure S1 from A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
Authors: Tien An-Chi , Li Jing , Bao Xun , Derogatis Alanna , Kim Seongho , Mehta Shwetal , Sanai Nader
Published: April 2023

Pharmacodynamic analysis of surgical glioblastoma tissue after short-term ribociclib treatment
Supplementary Data from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Authors: Recondo Gonzalo , Mezquita Laura , Facchinetti Francesco , Planchard David , Gazzah Anas , Bigot Ludovic , Rizvi Ahsan Z. , Frias Rosa L. , Thiery Jean Paul , Scoazec Jean-Yves , Sourisseau Tony , Howarth Karen , Deas Olivier , Samofalova Dariia , Galissant Justine , Tesson Pauline , Braye Floriane , Naltet Charles , Lavaud Pernelle , Mahjoubi Linda , Abou Lovergne Aurélie , Vassal Gilles , Bahleda Rastilav , Hollebecque Antoine , Nicotra Claudio , Ngo-Camus Maud , Michiels Stefan , Lacroix Ludovic , Richon Catherine , Auger Nathalie , De Baere Thierry , Tselikas Lambros , Solary Eric , Angevin Eric , Eggermont Alexander M. , Andre Fabrice , Massard Christophe , Olaussen Ken A. , Soria Jean-Charles , Besse Benjamin , Friboulet Luc
Published: April 2023

Supplementary figures legends
Figure S6 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 6. Deleterious structural rearrangements detected in MSH2, MSH6, and MLH1.
Supplemental legend from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers
Authors: Nevler Avinoam , Muller Alexander J. , Sutanto-Ward Erika , DuHadaway James B. , Nagatomo Kei , Londin Eric , O'Hayer Kevin , Cozzitorto Joseph A. , Lavu Harish , Yeo Theresa P. , Curtis Mark , Villatoro Tatiana , Leiby Benjamin E. , Mandik-Nayak Laura , Winter Jordan M. , Yeo Charles J. , Prendergast George C. , Brody Jonathan R.
Published: April 2023

Supplemental legend
Figure S10 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 10. Detection of ctDNA-based somatic alterations in archival primary tissue mutation.
Supplementary Figure 2 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Figure 2: CONSORT diagram for patients and specimens from both fresh-frozen and FFPE clinical validation cohorts. A) Fresh-frozen cohort (cohort-1), B) FFPE cohort (cohorts 2 and 3).
Supplementary Table S8 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Supplementary Fig. S8 and S9.
Supplementary Methods from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Authors: Cowman Sophie J. , Fuja Daniel G. , Liu Xian-De , Tidwell Rebecca S. Slack , Kandula Neelima , Sirohi Deepika , Agarwal Archana M. , Emerson Lyska L. , Tripp Sheryl R. , Mohlman Jeffrey S. , Stonhill Miekan , Garcia Guillermina , Conley Christopher J. , Olalde Adam A. , Sargis Timothy , Ramirez-Torres Adela , Karam Jose A. , Wood Christopher G. , Sircar Kanishka , Tamboli Pheroze , Boucher Kenneth , Maughan Benjamin , Spike Benjamin T. , Ho Thai H. , Agarwal Neeraj , Jonasch Eric , Koh Mei Yee
Published: April 2023

Additional methods
Supplemental Material from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Authors: Higgs Brandon W. , Morehouse Christopher A. , Streicher Katie , Brohawn Philip Z. , Pilataxi Fernanda , Gupta Ashok , Ranade Koustubh
Published: April 2023

Supplemental Material
Supplementary Figure 7 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 7. Phenotypic markers on isolated human T cells. Human T cells were isolated from healthy donor PBMCs. The cells were left untouched (naÃƒÂ¯ve), treated with IL-2 (100U/mL) or exposed to IL-2 + CD2/CD3/CD28 activation tetramers for up to 14 days. Following treatment, cells were assessed for A. PD-1, B. Tim-3, C. CTLA-4, or D. IFN-ÃŽÂ³ expression via FACS (n = 3 replicates). Over time, the activated T cells show diminished IFN-ÃŽÂ³ expression but increased and sustained expression of inhibitory markers: PD-1, Tim-3, and CTLA-4. These results represent a more physiologically relevant, exhausted T cell phenotype necessary to investigate the PD-1/PD-L1 relationship in our experimental setup.
Supplementary Figures from Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Authors: Hensley Martee L. , Chavan Shweta S. , Solit David B. , Murali Rajmohan , Soslow Robert , Chiang Sarah , Jungbluth Achim A. , Bandlamudi Chaitanya , Srinivasan Preethi , Tap William D. , Rosenbaum Evan , Taylor Barry S. , Donoghue Mark T.A. , Hyman David M.
Published: April 2023

Supplementary Figures
Figure S4 from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Suppl. Fig. 4. Flow cytometry analysis of immune populations
Figure S1 from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Suppl. Fig. 1. Flow-cytometric characterization of genetically modified MSCs
Table S4 from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

List of relatively enriched pathways for each transcriptional component forming the Onco-GPS map.
Figure S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Correlation of baseline IL6 levels(pg/mL) with IL6 levels collected on day of axi-cel infusion (A) and peak levels (B)
Supplementary Figure 1S - Real time cell growth monitorization of synovial sarcoma SW982 cells upon sequential treatment with nilotinib and doxorubicin. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Authors: Alemany Regina , Moura David S. , Redondo Andres , Martinez-Trufero Javier , Calabuig Silvia , Saus Carlos , Obrador-Hevia Antonia , Ramos Rafael , Villar Victor H. , Valverde Claudia , Vaz Maria Angeles , Medina Javier , Felipe-Abrio Irene , Hindi Nadia , Taron Miguel , Martin-Broto Javier
Published: April 2023

SW982 cells were treated with vehicle (DMSO), nilotinib (10 µM) or doxorubicin (0.1 µM). For sequential treatment, cells were pre-treated with nilotinib (10 µM) for 72 h, and then doxorubicin (0.1 µM) was added. Cell growth was continuously monitored using the RTCA MP Instrument. Cell Index (CI) values were normalized to the CI value at the time point of compound addition indicated by the black solid line. The CI profiles of treated cells reflect the initial cell attachment, logarithmic growth phase and response to the respective treatments. Error bars show the standard deviation of the mean of triplicates.
Table S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Super-enhancer analysis based on H3K27Ac ChIP-seq in U2-OS and SJSA-1 cells.
Table S2 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

AR, ERG, and PTEN status on MDA PCa PDXs
Table S1 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

Clinical information and pathologic diagnosis of one human donor for 2 cell lines and of 47 human donors for 80 PDXs
Table S4 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Authors: Shi Donghua , Shi Yaoping , Kaseb Ahmed O. , Qi Xingxing , Zhang Yuan , Chi Jiachang , Lu Qing , Gao Huiping , Jiang Hua , Wang Huamao , Yuan Daijing , Ma Hong , Wang Hongyang , Li Zonghai , Zhai Bo
Published: April 2023

The incidence of AEs in the HCC patients
Table S1 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Authors: Shi Donghua , Shi Yaoping , Kaseb Ahmed O. , Qi Xingxing , Zhang Yuan , Chi Jiachang , Lu Qing , Gao Huiping , Jiang Hua , Wang Huamao , Yuan Daijing , Ma Hong , Wang Hongyang , Li Zonghai , Zhai Bo
Published: April 2023

Lymphodepletion regimens received by the HCC patients
Protocol of Study 1 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Authors: Shi Donghua , Shi Yaoping , Kaseb Ahmed O. , Qi Xingxing , Zhang Yuan , Chi Jiachang , Lu Qing , Gao Huiping , Jiang Hua , Wang Huamao , Yuan Daijing , Ma Hong , Wang Hongyang , Li Zonghai , Zhai Bo
Published: April 2023

CG1001- CAR-GPC3 T cells clinical trial
Supplementary Data from RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia
Authors: Anande Govardhan , Deshpande Nandan P. , Mareschal Sylvain , Batcha Aarif M.N. , Hampton Henry R. , Herold Tobias , Lehmann Soren , Wilkins Marc R. , Wong Jason W.H. , Unnikrishnan Ashwin , Pimanda John E.
Published: April 2023

Supplementary Methods - revised, plus Supplementary Tables 1-6
Table S2 from Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
Authors: Matsuda Tatsuo , Leisegang Matthias , Park Jae-Hyun , Ren Lili , Kato Taigo , Ikeda Yuji , Harada Makiko , Kiyotani Kazuma , Lengyel Ernst , Fleming Gini F. , Nakamura Yusuke
Published: April 2023

List of predicted neoantigen peptides in 7 ovarian cancer patients.
Figure S2 from Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
Authors: Matsuda Tatsuo , Leisegang Matthias , Park Jae-Hyun , Ren Lili , Kato Taigo , Ikeda Yuji , Harada Makiko , Kiyotani Kazuma , Lengyel Ernst , Fleming Gini F. , Nakamura Yusuke
Published: April 2023

HLA-restricted activity of TCR-engineered T cells.
Supplementary Figure S8 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Authors: Pirker Christine , Bilecz Agnes , Grusch Michael , Mohr Thomas , Heidenreich Barbara , Laszlo Viktoria , Stockhammer Paul , Lötsch-Gojo Daniela , Gojo Johannes , Gabler Lisa , Spiegl-Kreinecker Sabine , Dome Balazs , Steindl Ariane , Klikovits Thomas , Hoda Mir Alireza , Jakopovic Marko , Samarzija Miroslav , Mohorcic Katja , Kern Izidor , Kiesel Barbara , Brcic Luka , Oberndorfer Felicitas , Müllauer Leonhard , Klepetko Walter , Schmidt Wolfgang M. , Kumar Rajiv , Hegedus Balazs , Berger Walter
Published: April 2023

Supplementary Figure S8. BAP1 expression in MPM samples and its relation to TERT promoter status and patient overall survival.
Supplementary Figure S5 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Authors: Pirker Christine , Bilecz Agnes , Grusch Michael , Mohr Thomas , Heidenreich Barbara , Laszlo Viktoria , Stockhammer Paul , Lötsch-Gojo Daniela , Gojo Johannes , Gabler Lisa , Spiegl-Kreinecker Sabine , Dome Balazs , Steindl Ariane , Klikovits Thomas , Hoda Mir Alireza , Jakopovic Marko , Samarzija Miroslav , Mohorcic Katja , Kern Izidor , Kiesel Barbara , Brcic Luka , Oberndorfer Felicitas , Müllauer Leonhard , Klepetko Walter , Schmidt Wolfgang M. , Kumar Rajiv , Hegedus Balazs , Berger Walter
Published: April 2023

Supplementary Figure S5: Impact of TERT promoter status on sensitivity of MPM cell models against pharmacological telomerase and ETS factor inhibition.
Figure S1 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Supplementary Figure 1
Supplementary Data from Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer
Authors: Kaur Harsimar , Salles Daniela C. , Murali Sanjana , Hicks Jessica L. , Nguyen Minh , Pritchard Colin C. , De Marzo Angelo M. , Lanchbury Jerry S. , Trock Bruce J. , Isaacs William B. , Timms Kirsten M. , Antonarakis Emmanuel S. , Lotan Tamara L.
Published: April 2023

Supplementary Table S2
Supplementary Data from Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Authors: Yaeger Rona , Kotani Daisuke , Mondaca Sebastián , Parikh Aparna R. , Bando Hideaki , Van Seventer Emily E. , Taniguchi Hiroya , Zhao HuiYong , Thant Claire N. , de Stanchina Elisa , Rosen Neal , Corcoran Ryan B. , Yoshino Takayuki , Yao Zhan , Ebi Hiromichi
Published: April 2023

Supplementary Table S1 to S4 and Supplementary Figure S1 to S3 Supplementary Table S1. Classification of BRAF variants identified in this study Supplementary Table S2. Patient characteristics based on BRAF classification Supplementary Table S3. Characteristics of patients treated with anti-EGFR antibody therapy Supplementary TableS4. Response to anti-EGFR antibody therapy based on BRAF classification and the sidedness of the tumor Supplementary Fig. S1. CONSORT diagram. Supplementary Fig. S2. Onco-print showing the alterations identified in 96 specimens from 118 patients analyzed for OS. Supplementary Fig. S3. OS in all patients with BRAFnon-V600 mutation (A) and stratified by RASmutation (B), or stratified by BRAFclassification in patients with RASwild-type tumors (C).
Table S2 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Authors: Iglesias-Gato Diego , Thysell Elin , Tyanova Stefka , Crnalic Sead , Santos Alberto , Lima Thiago S. , Geiger Tamar , Cox Jürgen , Widmark Anders , Bergh Anders , Mann Matthias , Flores-Morales Amilcar , Wikström Pernilla
Published: April 2023

Table S2
Suppl FigS3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Authors: Iglesias-Gato Diego , Thysell Elin , Tyanova Stefka , Crnalic Sead , Santos Alberto , Lima Thiago S. , Geiger Tamar , Cox Jürgen , Widmark Anders , Bergh Anders , Mann Matthias , Flores-Morales Amilcar , Wikström Pernilla
Published: April 2023

Suppl FigS3
Suppl FigS1 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Authors: Iglesias-Gato Diego , Thysell Elin , Tyanova Stefka , Crnalic Sead , Santos Alberto , Lima Thiago S. , Geiger Tamar , Cox Jürgen , Widmark Anders , Bergh Anders , Mann Matthias , Flores-Morales Amilcar , Wikström Pernilla
Published: April 2023

Suppl FigS1
Supplement 5 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

OS from first PD to death
Supplementary Figure S1 from Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer
Authors: Armstrong Cameron M. , Liu Chengfei , Liu Liangren , Yang Joy C. , Lou Wei , Zhao Ruining , Ning Shu , Lombard Alan P. , Zhao Jinge , D'Abronzo Leandro S. , Evans Christopher P. , Li Pui-Kai , Gao Allen C.
Published: April 2023

STS activity
Table S4 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Multivariate analysis of Progression Free Survival of patients with BRAFV600E mCRC with therapy forced into model.
Supplementary Table S3 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Analysis of deviance comparing models with and without genome instability parameters.
Supplemental Table 2 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Authors: Mao Pingping , Cohen Ofir , Kowalski Kailey J. , Kusiel Justin G. , Buendia-Buendia Jorge E. , Cuoco Michael S. , Exman Pedro , Wander Seth A. , Waks Adrienne G. , Nayar Utthara , Chung Jon , Freeman Samuel , Rozenblatt-Rosen Orit , Miller Vincent A. , Piccioni Federica , Root David E. , Regev Aviv , Winer Eric P. , Lin Nancy U. , Wagle Nikhil
Published: April 2023

GSEA list
Supplemental Table 10 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Authors: Mao Pingping , Cohen Ofir , Kowalski Kailey J. , Kusiel Justin G. , Buendia-Buendia Jorge E. , Cuoco Michael S. , Exman Pedro , Wander Seth A. , Waks Adrienne G. , Nayar Utthara , Chung Jon , Freeman Samuel , Rozenblatt-Rosen Orit , Miller Vincent A. , Piccioni Federica , Root David E. , Regev Aviv , Winer Eric P. , Lin Nancy U. , Wagle Nikhil
Published: April 2023

Gene sets defined and used in this study and Signature strength per sample
Supplementary Materials from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Authors: Nayak Lakshmi , Molinaro Annette M. , Peters Katherine , Clarke Jennifer L. , Jordan Justin T. , de Groot John , Nghiemphu Leia , Kaley Thomas , Colman Howard , McCluskey Christine , Gaffey Sarah , Smith Timothy R. , Cote David J. , Severgnini Mariano , Yearley Jennifer H. , Zhao Qing , Blumenschein Wendy M. , Duda Dan G. , Muzikansky Alona , Jain Rakesh K. , Wen Patrick Y. , Reardon David A.
Published: April 2023

Supplemental Text
Supplementary Figures S1 to S5 and methods from Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Authors: Kanikarla Marie Preeti , Haymaker Cara , Parra Edwin Roger , Kim Young Uk , Lazcano Rossana , Gite Swati , Lorenzini Daniele , Wistuba Ignacio I. , Tidwell Rebecca S. Slack , Song Xiaofei , Foo Wai Chin , Maru Dipen M. , Chun Yun Shin , Futreal Andy , Kee Bryan , Menter David , Solis Luisa , Tzeng Ching-Wei , Parseghian Christine , Raghav Kanwal , Morris Van , Chang Chia-Chi , Jenq Robert , Tam Alda , Bernatchez Chantale , Kopetz Scott , Vauthey Jean-Nicolas , Overman Michael J.
Published: April 2023

Supplementary figures and supplemental methods
Supplementary Legend from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Authors: Schoenfeld Adam J. , Bandlamudi Chai , Lavery Jessica A. , Montecalvo Joseph , Namakydoust Azadeh , Rizvi Hira , Egger Jacklynn , Concepcion Carla P. , Paul Sonal , Arcila Maria E. , Daneshbod Yahya , Chang Jason , Sauter Jennifer L. , Beras Amanda , Ladanyi Marc , Jacks Tyler , Rudin Charles M. , Taylor Barry S. , Donoghue Mark T.A. , Heller Glenn , Hellmann Matthew D. , Rekhtman Natasha , Riely Gregory J.
Published: April 2023

Supplementary Legend
Figure S3 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Volume curves for all patients integrating pre and under treatment 3D volume data by central review. *patients with drugs intake < 2 months ** pre/post operative MRI non-available
Supplementary Figure 2B from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Authors: Davids Matthew S. , Kuss Bryone J. , Hillmen Peter , Montillo Marco , Moreno Carol , Essell James , Lamanna Nicole , Nagy Zsolt , Tam Constantine S. , Stilgenbauer Stephan , Ghia Paolo , Delgado Julio , Lustgarten Stephanie , Weaver David T. , Youssoufian Hagop , Jäger Ulrich
Published: April 2023

Figure S2B displays probability of progression-free survival over time in subgroups of patients with and without trisomy 12
Fig S2 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Authors: Di Giacomo Anna Maria , Chiarion-Sileni Vanna , Del Vecchio Michele , Ferrucci Pier Francesco , Guida Michele , Quaglino Pietro , Guidoboni Massimo , Marchetti Paolo , Cutaia Ornella , Amato Giovanni , Covre Alessia , Camerini Roberto , Calabrò Luana , Valente Monica , Giannarelli Diana , Mandalà Mario , Maio Michele
Published: April 2023

Swimmer plot analysis of NIBIT-M2 patients. Swimmer plot showing by study arm patients who at the time of data cut-off were alive and either still on study therapy (n=7) or off study therapy without having received subsequent treatment (n=6), and all patients who had received subsequent treatment at the time of data cut-off, regardless of whether alive or dead (n=32). Patients excluded from the plot (n=31) died without receiving any subsequent therapy.
Supplementary Figure 1 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
Authors: Sharda Anish V. , Bogue Thomas , Barr Alexandra , Mendez Lourdes M. , Flaumenhaft Robert , Zwicker Jeffrey I.
Published: April 2023

PDI ELISA does not detect vascular thiol isomerases ERp5 and ERp57
Supplementary Methods from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

Methods describing MRI protocols, Image acquisition, and analysis, IHC analysis and cDNA library preparation.
Supplementary Data from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
Authors: Fontana Francesca , Scott Michael J. , Allen John S. , Yang Xiaoxia , Cui Grace , Pan Dipanjan , Yanaba Noriko , Fiala Mark A. , O'Neal Julie , Schmieder-Atteberry Anne H. , Ritchey Julie , Rettig Michael , Simons Kathleen , Fletcher Steven , Vij Ravi , DiPersio John F. , Lanza Gregory M.
Published: April 2023

Supplemental Methods
Suppl Figure 5 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
Authors: Fontana Francesca , Scott Michael J. , Allen John S. , Yang Xiaoxia , Cui Grace , Pan Dipanjan , Yanaba Noriko , Fiala Mark A. , O'Neal Julie , Schmieder-Atteberry Anne H. , Ritchey Julie , Rettig Michael , Simons Kathleen , Fletcher Steven , Vij Ravi , DiPersio John F. , Lanza Gregory M.
Published: April 2023

Supplemental Figure 5 Color
Supplementary fig 4 from Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Baptista Maria Joao , Baskar Sivasubramanian , Gaglione Erika M. , Keyvanfar Keyvan , Ahn Inhye E. , Wiestner Adrian , Sun Clare
Published: April 2023

Expansion of T cells under different conditions. Total CD3+, CD8+, CD4+ counts at Day 0 and Day 7 of expansion in the presence of anti-CD3/CD28/CD137 beads or autologous CLL cells.
Supplementary fig 3 from Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Baptista Maria Joao , Baskar Sivasubramanian , Gaglione Erika M. , Keyvanfar Keyvan , Ahn Inhye E. , Wiestner Adrian , Sun Clare
Published: April 2023

(A) Frequency of predominant clonotypes as detected by NGS and of the corresponding CD8+ TRBV families as measured by flow cytometry. Grey bars indicate TRBV families that did not have commercially available fluorescent-labelled antibodies. (B) Pie chart of the most expanded clonotypes and expression of granzyme B (GrB). CD8+ GrB+ clonotypes comprising >2% of the repertoire at the time of response are shown in color.-
Figure S5 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

Correlation between duration of clinical benefit (DOCB) and overall survival (OS) for the standard RANO, iRANO, and mRANO criteria. (A) Correlation between radiographic DOCB using the standard RANO criteria applied to local measurements and OS for patients who died. (B) Correlation between radiographic DOCB using the iRANO criteria applied to local measurements and OS for patients who died. (C) Correlation between radiographic DOCB using the mRANO criteria applied to local measurements and OS for patients who died. (D) Correlation between radiographic DOCB using the standard RANO criteria applied to IRF-determined measurements and OS for patients who died. (E) Correlation between radiographic DOCB using the iRANO criteria applied to IRF-determined measurements and OS for patients who died. (F) Correlation between radiographic DOCB using the mRANO criteria applied to IRF-determined measurements and OS for patients who died. Solid circles = patients who progressed. Open circles = patients who were censored (not used in correlation analysis, only for visualization purposes).
Supplementary Figure 4 from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Authors: Mudianto Tenny , Campbell Katie M. , Webb Jason , Zolkind Paul , Skidmore Zachary L. , Riley Rachel , Barnell Erica K. , Ozgenc Ibrahim , Giri Tusar , Dunn Gavin P. , Adkins Douglas R. , Griffith Malachi , Egloff Ann Marie , Griffith Obi L. , Uppaluri Ravindra
Published: April 2023

Supplementary Figure 4
Supplementary Table 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

S Table 1
Supplementary Figure 1 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Authors: DeCensi Andrea , Puntoni Matteo , Johansson Harriet , Guerrieri-Gonzaga Aliana , Caviglia Silvia , Avino Franca , Cortesi Laura , Ponti Antonio , Pacquola Maria Grazia , Falcini Fabio , Gulisano Marcella , Digennaro Maria , Cariello Anna , Cagossi Katia , Pinotti Graziella , Lazzeroni Matteo , Serrano Davide , Briata Irene Maria , Buttiron Webber Tania , Boni Luca , Bonanni Bernardo
Published: April 2023

CONSORT Diagram
Supplementary Figure 8 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

Expression of PGC1α in cerulean treated and control WT mice pancreas.
Supplementary Figure 14 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

Gnas induction elevates stemness in IPMN cells